AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.

Saved in:
Bibliographic Details
Title: AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.
Authors: Rabe KF; LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany.; Christian-Albrechts University of Kiel, Airway Research Center North, Kiel, Germany.; German Center for Lung Research, Grosshansdorf, Germany., Martinez FJ; Weill Cornell Medical College, New York, NY, USA., Bhatt SP; University of Alabama at Birmingham, Birmingham, AL, USA., Kawayama T; Kurume University School of Medicine, Fukuoka, Japan., Cosio BG; Hospital Universitario Son Espases-IdISBa-CIBERES, Palma de Mallorca, Spain., Mroz RM; Medical University of Bialystok, Bialystok, Poland., Boomsma MM; Sanofi, Amsterdam, Netherlands., Goulaouic H; Sanofi, Chilly-Mazarin, France., Nivens MC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Djandji M; Sanofi, Cambridge, MA, USA., Soler X; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Liu Y; Sanofi, Bridgewater, NJ, USA., Kosloski MP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Xu CR; Sanofi, Bridgewater, NJ, USA., Amin N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Staudinger H; Sanofi, Bridgewater, NJ, USA., Lederer DJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Abdulai RM; Former Sanofi employee.
Source: ERJ open research [ERJ Open Res] 2024 Sep 23; Vol. 10 (5). Date of Electronic Publication: 2024 Sep 23 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 101671641 Publication Model: eCollection Cited Medium: Print ISSN: 2312-0541 (Print) Linking ISSN: 23120541 NLM ISO Abbreviation: ERJ Open Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2312-0541
DOI:10.1183/23120541.00718-2023